Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 9 years
- Director since
- 2023
9 years of board service in total across 4 boards, counting each seat separately. Longest: Kura Oncology Inc., 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
53.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Kura Oncology Inc. June 4, 202666.2%
-
TriSalus Life Sciences Inc. May 14, 202692.3%
-
Kura Oncology Inc. May 31, 202399.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 5, 2026 | TriSalus Life Sciences Inc. | Shares withheld for tax | −2,693 | $4.38 | $11,795 |
| Jun 30, 2026 | TriSalus Life Sciences Inc. | Grant or award | +3,990 | $3.87 | $15,441 |
| Jun 30, 2026 | Absci Corporation | Open-market purchase | +12,900 | $11.54 | $148,866 |
| Jun 4, 2026 | Absci Corporation | Grant or award | +10,100 | — | — |
| May 15, 2026 | TriSalus Life Sciences Inc. | Open-market purchase | +39,682 | $2.59 | $102,776 |
| Mar 17, 2026 | TriSalus Life Sciences Inc. | Open-market sale | −15,944 | $3.85 | $61,384 |
| Mar 11, 2026 | TriSalus Life Sciences Inc. | Open-market sale | −4,358 | $4.13 | $17,999 |
| Feb 23, 2026 | TriSalus Life Sciences Inc. | Open-market purchase | +30,487 | $4.10 | $124,997 |
| Dec 31, 2025 | TriSalus Life Sciences Inc. | Grant or award | +2,100 | $4.38 | $9,198 |
| Nov 24, 2025 | TriSalus Life Sciences Inc. | Grant or award | +125,000 | — | — |
| Nov 24, 2025 | TriSalus Life Sciences Inc. | Grant or award | +300,000 | — | — |
| Jun 30, 2025 | TriSalus Life Sciences Inc. | Grant or award | +2,848 | $4.23 | $12,047 |
| Feb 18, 2025 | TriSalus Life Sciences Inc. | Grant or award | +21,089 | — | — |
| Jan 30, 2025 | TriSalus Life Sciences Inc. | Open-market purchase | +5,010 | $5.28 | $26,453 |
| Jan 29, 2025 | TriSalus Life Sciences Inc. | Open-market purchase | +5,030 | $5.03 | $25,301 |
Questions about Mary T. Szela
What boards is Mary T. Szela on?
Mary T. Szela sits on the boards of Absci Corporation, Averin Capital Acquisition Corp., Kura Oncology Inc. and TriSalus Life Sciences Inc.
What company is Mary T. Szela the CEO of?
Mary T. Szela has been CEO and President of TriSalus Life Sciences Inc. since August 2023.
How long has Mary T. Szela served on boards?
Our records show at least 9 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.